Supplementary to the publication mentioned above

Supplementary to the publication mentioned above

Supplementary to the publication mentioned above

Supplementary to the publication mentioned above

In order to find new therapeutic options in anaplastic thyroid cancer, all FDA-approved drugs for any cancer therapy were identified by searching the databases of National Cancer Institute and MyCancerGenome. Finally, 129 FDA/EMA-approved drugs targeting cancer genetic alterations were included. These drug lists were linked to 128 genes by querying databases of MD Anderson Cancer Center and Drugbank, which encode the potential sites of binding and action. Moreover, special attention was given to specific genetic alterations resulting in either drug sensitivity or drug resistance of targeted therapy. Hereby the expert-crowdsourced, publication-based databases from MyCancerGenome, CIViC, TARGET and OncoKB were mined.

In order to find new therapeutic options in anaplastic thyroid cancer, first all FDA-approved drugs for any cancer therapy were identified by searching the databases of National Cancer Institute and MyCancerGenome (database query 09/2021). Unspecific drugs such as Tretinoin or Cabazitaxel were excluded (Supplementary Table 1). Finally, 155 FDA/EMA-approved drugs targeting cancer genetic alterations were included. These drug lists were linked to 136 genes by querying databases of MD Anderson Cancer Center and Drugbank, which encode the potential sites of binding and action (Supplementary Table 1). Moreover, special attention was given to specific genetic alterations resulting in either drug sensitivity or drug resistance of targeted therapy. Hereby the expert-crowdsourced, publication-based databases from MyCancerGenome, CIViC, TARGET and OncoKB (Supplementary Table 2) were mined.

In order to find new therapeutic options in anaplastic thyroid cancer, first all FDA-approved drugs for any cancer therapy were identified by searching the databases of National Cancer Institute and MyCancerGenome (database query 09/2021). Unspecific drugs such as Tretinoin or Cabazitaxel were excluded (Supplementary Table 1(11)). Finally, 155 FDA/EMA-approved drugs targeting cancer genetic alterations were included. These drug lists were linked to 136 genes by querying databases of MD Anderson Cancer Center and Drugbank, which encode the potential sites of binding and action (Supplementary Table 1). Moreover, special attention was given to specific genetic alterations resulting in either drug sensitivity or drug resistance of targeted therapy. Hereby the expert-crowdsourced, publication-based databases from MyCancerGenome, CIViC, TARGET and OncoKB (Supplementary Table 2) were mined. @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-536859905 -1073732485 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin-top:0cm; margin-right:0cm; margin-bottom:10.0pt; margin-left:0cm; line-height:115%; mso-pagination:widow-orphan; font-size:11.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:DE; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-size:11.0pt; mso-ansi-font-size:11.0pt; mso-bidi-font-size:11.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:DE; mso-fareast-language:EN-US;}.MsoPapDefault {mso-style-type:export-only; margin-bottom:10.0pt; line-height:115%;}div.WordSection1 {page:WordSection1;}

In order to find new therapeutic options in anaplastic thyroid cancer, first all FDA-approved drugs for any cancer therapy were identified by searching the databases of National Cancer Institute and MyCancerGenome (database query 09/2021). Unspecific drugs such as Tretinoin or Cabazitaxel were excluded (Supplementary Table 1). Finally, 155 FDA/EMA-approved drugs targeting cancer genetic alterations were included. These drug lists were linked to 136 genes by querying databases of MD Anderson Cancer Center and Drugbank, which encode the potential sites of binding and action (Supplementary Table 1). Moreover, special attention was given to specific genetic alterations resulting in either drug sensitivity or drug resistance of targeted therapy. Hereby the expert-crowdsourced, publication-based databases from MyCancerGenome, CIViC, TARGET and OncoKB (Supplementary Table 2) were mined.

In order to find new therapeutic options in anaplastic thyroid cancer, first all FDA-approved drugs for any cancer therapy were identified by searching the databases of National Cancer Institute and MyCancerGenome (database query 09/2021). Unspecific drugs such as Tretinoin or Cabazitaxel were excluded (Supplementary Table 1). Finally, 155 FDA/EMA-approved drugs targeting cancer genetic alterations were included. These drug lists were linked to 136 genes by querying databases of MD Anderson Cancer Center and Drugbank, which encode the potential sites of binding and action (Supplementary Table 1). Moreover, special attention was given to specific genetic alterations resulting in either drug sensitivity or drug resistance of targeted therapy. Hereby the expert-crowdsourced, publication-based databases from MyCancerGenome, CIViC, TARGET and OncoKB (Supplementary Table 2) were mined.

In order to find new therapeutic options in anaplastic thyroid cancer, first all FDA-approved drugs for any cancer therapy were identified by searching the databases of National Cancer Institute and MyCancerGenome (database query 09/2021). Unspecific drugs such as Tretinoin or Cabazitaxel were excluded (Supplementary Table 1). Finally, 155 FDA/EMA-approved drugs targeting cancer genetic alterations were included. These drug lists were linked to 136 genes by querying databases of MD Anderson Cancer Center and Drugbank, which encode the potential sites of binding and action (Supplementary Table 1). Moreover, special attention was given to specific genetic alterations resulting in either drug sensitivity or drug resistance of targeted therapy. Hereby the expert-crowdsourced, publication-based databases from MyCancerGenome, CIViC, TARGET and OncoKB (Supplementary Table 2) were mined.